Study of AVZO-021 in Patients With Advanced Solid Tumors
A phase 1/2 trial of AVZO-021, Palbociclib, Fulvestrant in ovarian cancer and endometrial cancer, run by Avenzo Therapeutics, Inc., now recruiting.
Overview
Study of AVZO-021 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05867251 by Avenzo Therapeutics, Inc., with 430 participants planned, started 2023-08-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib. Conditions listed: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Shares AVZO-021, Avenzo Therapeutics, Fulvestrant.
- TrialPF-07104091 as a Single Agent and in Combination Therapy
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Ovarian cancer.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant.
- TrialA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With
Shares Ribociclib, Abemaciclib, Palbociclib, Ovarian cancer.
- TrialOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Shares Abemaciclib, Fulvestrant, Ovarian cancer.